Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review (Q35054424)

6 August 2017

1 reference

title

Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review (English)

1 reference

6 August 2017

0 references

Meera Vaswani

1 reference

6 August 2017

Farzana Kadar Linda

series ordinal

1 reference

6 August 2017

Subramanyam Ramesh

series ordinal

1 reference

6 August 2017

publication date

1 February 2003

1 reference

Progress in Neuro-Psychopharmacology & Biological Psychiatry

6 August 2017

published in

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

85-102

1 reference

Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

The treatment of benzodiazepine dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Very High Cytochrome P4501A2 Activity and Nonresponse to Clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Paroxetine: a review.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Inpatient Treatment of Anorexia Nervosa: Review and Recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Drug-Metabolizing Enzymes and Therapeutic Drug Monitoring in Psychiatry

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Central and peripheral monoaminergic membrane-pump blockade by some addictive analgesics and antihistamines

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Birth outcomes in pregnant women taking fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Serotonin-specific drugs for anxiety and depressive disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Review of the animal pharmacology and pharmacokinetics of fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Feasibility and effectiveness of treatments for post-stroke depression in elderly inpatients: systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Binding of antidepressants to human brain receptors: focus on newer generation compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Response characteristics to antidepressants and placebo in post-traumatic stress disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Fluvoxamine in civilians with posttraumatic stress disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Fluvoxamine treatment for chronic PTSD: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Neuroendocrine and behavioral effects of dietary tryptophan restriction in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Pharmacokinetics of the newer antidepressants: clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Beyond specificity: effects of serotonin and serotonergic treatments on psychobiological dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Systematic review and guide to selection of selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Open trial of fluoxetine therapy for premenstrual syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Guillain-Barré syndrome following zimeldine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Anger attacks in unipolar depression, Part 1: Clinical correlates and response to fluoxetine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Sertraline in underweight binge eating/purging-type eating disorders: five case reports

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Fluoxetine, a selective inhibitor of serotonin uptake

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

1 reference

7 January 2021

Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Selective serotonin reuptake inhibitors in pregnancy and lactation

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Long-term treatment of double depression: a preliminary study with serotonergic antidepressants.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Pharmacokinetics of selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Pharmacologic Approaches in the Treatment of Eating Disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Selective serotonin reuptake inhibitors for children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

A review of the metabolism and pharmacokinetics of paroxetine in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Citalopram in the treatment of obsessive‐compulsive disorder: an open pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

The treatment of depressive states with G 22355 (imipramine hydrochloride).

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Movement Disorders Associated With the Serotonin Selective Reuptake Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Inhibition and induction of cytochrome P450 and the clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Paroxetine: pharmacokinetic and antidepressant effect in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Low CSF 5-HIAA concentrations and severe aggression and impaired impulse control in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Combining pharmacotherapy and psychotherapy in the treatment of patients with eating disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Clinical and physiological consequences of rapid tryptophan depletion

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Selective serotonin reuptake inhibitors in the treatment of paediatric anxiety disorders: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Studies on the Stereoselective Metabolism of Citalopram by Human Liver Microsomes and cDNA-Expressed Cytochrome P450 Enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Fluoxetine versus phenelzine in atypical depression

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Citalopram: a comprehensive review

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Sertraline 50 mg daily: the optimal dose in the treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Pharmacology of antidepressants--characteristics of the ideal drug

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Multiple serotonin receptors: clinical and experimental aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

The Role of Metabolites of Antidepressants in the Treatment of Depression

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p‐hydroxylation

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

History of serotonin and serotinin disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Molecular genetics of the human cytochrome P450 monooxygenase superfamily

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Selective serotonin reuptake inhibitors for late-life depression: a comparative review

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Non-linear fluvoxamine disposition

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Prozac: panacea or puzzle?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

The serotonin syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Are there special considerations in the prescription of serotonin reuptake inhibitors for women?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Emergence of intense suicidal preoccupation during fluoxetine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Anatomy of the serotonergic system

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Characteristics of fluvoxamine-induced nausea

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Clinical pharmacokinetics of selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Overview of the pharmacokinetics of fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Human cytochromes mediating N-demethylation of fluoxetine in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Paroxetine: an update of its use in psychiatric disorders in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

The Oral Dose-Effect Relationship for Fluvoxamine: a Fixed-Dose Comparison Against Placebo in Depressed Outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Selective serotonin re-uptake inhibitors for children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2802%2900338-X

7 January 2021

10.1016/S0278-5846(02)00338-X

Identifiers

DOI

1 reference

6 August 2017

1 reference